Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.16Last Year’s EPS
-1.89Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 12.75%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong confidence in the potential approval and market launch of taletrectinib. The company highlighted its robust financial position and pipeline development, although there were concerns about increased expenses and gaps in patient testing and diagnosis.Company Guidance
During the Nuvation Bio First Quarter 2025 Financial Results and Business Update Conference Call, the company provided extensive guidance on their upcoming plans and metrics. They are preparing for the potential FDA approval of taletrectinib on June 23, 2025, a ROS1 inhibitor targeting non-small-cell lung cancer, which has shown an 89% overall response rate (ORR) and a median progression-free survival (PFS) of 46 months in clinical trials. The team reported a cash runway of $461.7 million, with an additional $250 million in non-dilutive financing from Sagard Healthcare Partners, ensuring financial stability without needing further capital to achieve profitability. The company is focusing on commercial readiness with a team of 47 oncology account managers and expects to address an estimated U.S. market of 3,000 new ROS1 positive lung cancer patients annually. They emphasized the importance of metrics such as ORR, PFS, duration of response, and safety profile, alongside strategic priorities like educating healthcare providers and enhancing patient testing and identification.Potential FDA Approval of Taletrectinib
Taletrectinib, a next-generation ROS1 inhibitor, is under priority review by the FDA with a PDUFA date set for June 23, 2025. It has shown an 89% confirmed overall response rate and a median progression-free survival of 46 months in treatment-naïve patients.
Strong Financial Position
Nuvation Bio ended the quarter with $461.7 million in cash and marketable securities, excluding a $250 million non-dilutive financing agreement with Sagard Healthcare Partners. This positions the company well for the potential launch and further pipeline development without needing additional capital.
Commercial Readiness and Experienced Team
The commercial team is prepared for launch with a strategy focused on early use and long-term persistence, leveraging a team with extensive experience in launching oncology therapies.
Pipeline Development Beyond Taletrectinib
Nuvation Bio is advancing additional pipeline candidates, including safusidenib for IDH1 mutant glioma, NUV-1511 from its drug conjugate platform, and NUV-868, a BD2-selective BET inhibitor.
NUVB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NUVB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $2.04 | $2.10 | +2.94% |
Mar 06, 2025 | $1.89 | $2.02 | +6.88% |
Nov 06, 2024 | $2.54 | $2.62 | +3.15% |
Aug 05, 2024 | $3.36 | $3.18 | -5.36% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Nuvation Bio (NUVB) report earnings?
Nuvation Bio (NUVB) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Nuvation Bio (NUVB) earnings time?
Nuvation Bio (NUVB) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NUVB EPS forecast?
NUVB EPS forecast for the fiscal quarter 2025 (Q2) is -0.16.